3-[2-oxo-3-(4-piperidin-1-yl-phenyl)-imidazolidin-1-yl]-benzoic acid | 651749-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-[2-oxo-3-(4-piperidin-1-yl-phenyl)-imidazolidin-1-yl]-benzoic acid
• 英文别名: Benzoic acid, 3-[2-oxo-3-[4-(1-piperidinyl)phenyl]-1-imidazolidinyl]-；3-[2-oxo-3-(4-piperidin-1-ylphenyl)imidazolidin-1-yl]benzoic acid
• CAS: 651749-00-7
• 化学式: C₂₁H₂₃N₃O₃
• 分子量: 365.432
• InChiKey: MFPRVDJOQSBVDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基苯甲酸甲酯 在 copper(l) iodide sodium hydroxide 、 potassium phosphate 、 水 、 potassium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 DMF (N,N-dimethyl-formamide) 、 甲苯 为溶剂， 反应 43.0h， 生成 3-[2-oxo-3-(4-piperidin-1-yl-phenyl)-imidazolidin-1-yl]-benzoic acid
  参考文献：
  名称：

  [EN] UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS
  [FR] COMPOSES D'ACIDE BENZOIQUE A SUBSTITUTION UREIDO ET LEUR UTILISATION POUR LA SUPPRESSION DE NON-SENS ET LE TRAITEMENT DE MALADIE

  摘要：

  公开号：

  WO2004009558A3

文献信息

• Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
  申请人：Wilde G. Richard

  公开号：US20060167065A1

  公开（公告）日：2006-07-27

  The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.

  这项发明涵盖了尿素取代苯甲酸化合物，包括这些化合物的组合物以及通过给予这些化合物或组合物来治疗或预防与mRNA无义突变相关疾病的方法。
• UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE
  申请人：Wilde Richard G.

  公开号：US20080275233A1

  公开（公告）日：2008-11-06

  The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.

  本发明涵盖了尿素取代苯甲酸化合物，包括这些化合物的组合物和通过给予这些化合物或组合物治疗或预防与mRNA无意义突变相关的疾病的方法。
• METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH
  申请人：Almstead Neil G.

  公开号：US20110046136A1

  公开（公告）日：2011-02-24

  The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

  本发明涉及由核酸序列编码的功能性蛋白质，其中包括一个无意义突变。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能性蛋白质的方法，以及利用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
• METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH
  申请人：PTC THERAPEUTICS, INC

  公开号：US20160199357A1

  公开（公告）日：2016-07-14

  The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

  本发明涉及由包含无意义突变的核酸序列编码的功能蛋白质。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能蛋白质的方法，并使用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
• Therapeutic uses of dunaliella powder
  申请人：Nikken Sohonsha Corporation

  公开号：EP2269620A1

  公开（公告）日：2011-01-05

  A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear receptors.

  一种治疗选自糖尿病和动脉粥样硬化的疾病的方法，以及一种降低受试者血浆中甘油三酯和/或增加高密度脂蛋白胆固醇水平的方法。该方法包括向受试者施用有效量的杜纳利菌粗粉，可选择与核受体激活剂一起施用。